

Protalix BioTherapeutics, Inc.  
Form 8-K  
June 20, 2013

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): June 20, 2013**

---

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

|                                     |                                 |                            |
|-------------------------------------|---------------------------------|----------------------------|
| <b>Florida</b>                      | <b>001-33357</b>                | <b>65-0643773</b>          |
| <b>(State or other jurisdiction</b> | <b>(Commission File Number)</b> | <b>(IRS Employer</b>       |
| <b>of incorporation)</b>            |                                 | <b>Identification No.)</b> |

|                                                 |                   |
|-------------------------------------------------|-------------------|
| <b>2 Snunit Street</b>                          | <b>20100</b>      |
| <b>Science Park, POB 455</b>                    |                   |
| <b>Carmiel, Israel</b>                          |                   |
| <b>(Address of principal executive offices)</b> | <b>(Zip Code)</b> |

**Registrant's telephone number, including area code +972-4-988-9488**

**(Former name or former address, if changed since last report.)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

--Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

--Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

--Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

--Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure**

On June 20, 2013, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that it had held an Analyst Event on June 20, 2013 during which the Company disclosed new data regarding three new compounds in development, oral PRX-106 for immune mediated disorders, PRX-110 for Cystic Fibrosis (CF), and PRX-107 for emphysema from heredity alpha1-antitrypsin (AAT) deficiency.

The event audio and slide presentation will be archived on the Company’s website for a 30-day period. The webcast will be available at [www.protalix.com](http://www.protalix.com) on the Events Calendar page. The slides will be available under the presentation tab on the Company’s website.

A copy of the press release is furnished as Exhibit 99.1.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated June 20, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: June 20, 2013 By: /s/ David Aviezer, Ph.D.  
Name: David Aviezer, Ph.D.  
Title: President and Chief Executive Officer